VOR Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 76,360 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 16,361 shares of Vor Bio’s common stock to eight newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and the exercise price is $30.40 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit

Media & Investor Contacts:

Carl Mauch

Sarah Spencer



EN
03/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Confe...

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PTLocation: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the Company’s website ...

 PRESS RELEASE

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s...

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company’s recently announced $150M PIPE financing, which included participation from both investors....

 PRESS RELEASE

Vor Bio Announces $150 Million Private Placement

Vor Bio Announces $150 Million Private Placement BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-relat...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch